Capital Fund Management (CFM)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.8M Buy
391,900
+310,400
+381% +$13.3M 0.08% 348
2026
Q1
$3M Sell
81,500
-22,700
-22% -$1.08M 0.01% 1159
2025
Q4
$5.3M Sell
104,200
-349,200
-77% -$17.9M 0.01% 1171
2025
Q3
$25.2M Sell
453,400
-200
-0% -$11.7K 0.07% 417
2025
Q2
$31.3M Sell
453,600
-42,600
-9% -$2.9M 0.09% 330
2025
Q1
$34.5M Buy
496,200
+210,500
+74% +$17.4M 0.1% 281
2024
Q4
$24.6M Sell
285,700
-70,100
-20% -$7.58M 0.06% 415
2024
Q3
$42.4M Buy
355,800
+17,300
+5% +$2.31M 0.12% 235
2024
Q2
$48.3M Buy
338,500
+200,400
+145% +$26.6M 0.14% 197
2024
Q1
$17.7M Sell
138,100
-210,800
-60% -$25.1M 0.05% 493
2023
Q4
$36.1M Buy
348,900
+297,100
+574% +$29.4M 0.1% 291
2023
Q3
$4.71M Buy
+51,800
New +$4.56M 0.02% 964
2022
Q1
– Sell
-43,600
Closed -$2.44M – 1686
2021
Q4
$2.44M Sell
43,600
-11,200
-20% -$607K 0.02% 952
2021
Q3
$2.63M Buy
+54,800
New +$2.65M 0.02% 813
2018
Q2
– Sell
-15,200
Closed -$374K – 2202
2018
Q1
$374K Buy
+15,200
New +$399K ﹤0.01% 1559
2017
Q4
– Sell
-16,200
Closed -$390K – 1930
2017
Q3
$390K Buy
+16,200
New +$366K ﹤0.01% 1254

Other funds holding NVO

Capital Fund Management (CFM)'s NVO Position: Q2 2026 in Review

Capital Fund Management (CFM) sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 549,373 shares — an estimated $23.6M sold.

Capital Fund Management (CFM) first reported a position in NVO in Q2 2013 and held it in 41 quarters. The position peaked at $98.7M in Q1 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Capital Fund Management (CFM) reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 549,373 Novo Nordisk shares in Q2 2026, an estimated $23.6M.
  • Capital Fund Management (CFM) first reported a position in Novo Nordisk in Q2 2013 and held it in 41 quarters.
  • Capital Fund Management (CFM)'s Novo Nordisk position peaked at $98.7M in Q1 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.